Skip to main content
Equibles
ACTU logo

ACTU · Actuate Therapeutics, Inc.

Track ACTU — free

Use ACTU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACTU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.68 -0.05 (-6.24%) At close · Oct 8
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$17.39M
Shares
24.01M
Volume · Oct 8 324.46K Avg daily vol (3M) 391.22K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.68 Open$0.68 Day$0.62–0.72 52W close$0.62–8.09 Avg vol 30d302K Short int1.1M · 4.6% float · 3.2d Short vol69% DataAug 2024–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$20.45M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$4.43M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.5%
Year over year · more shares
Price change (1Y)
-89.7%
Trailing year
Short interest
4.6%
Latest settlement · 3.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.4 · calm Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −74%
below
Price vs 50-day avg −37%
below
RSI (14) 37
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −41%
trailing
6-month return −71%
trailing
YTD return −89%
this year
Relative strength −80%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
3 of 62 funds reported for Sep 30 · net -111 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.57% of float · ▼ -6.4% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
62 holders — near 2-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 108%
annualized · 1-yr
Max drawdown −92%
past year
ATR 21.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−74% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
37 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
3 of 62 funds reported for Sep 30 · net -111 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.57% of float · ▼ -6.4% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
62 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $8
vs 200-day avg -74% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACTU
Actuate Therapeutics, Inc.
this stock
$17.39M -88.9% — — 4.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.16B +11.0% +46.2% 29.5 1.9%
MRNA
Moderna, Inc.
 $78.65B +568.0% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.14B -4.2% +20.8% 18.3 2.5%
CSLLY
Csl Ltd
 $60.24B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
60
% held
56.0%
Reported
3 of 62
Top holder
BIOS Capital Management,…
Held Float
View
Held by Funds
Fund positions
30
View
Short & Settlement
Short Interest Falling
Shares short
1.1M
Days to cover
3.2d
Change
-75.3K sh
View
Short Volume
Short vol %
69%
As of
Oct 8, 2026
Short Total
View
Fails to Deliver
FTD shares
86
Value
$92
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
64.5%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-22.2M
EPS diluted
$-1.06
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 14, 2026
This year
9
View
Proposed Sales
Value
$2.1M
Shares
280.0K
Filed
Dec 11, 2025
View
Exempt Offerings
Offering
$9.3M
Filed
Jul 7, 2025
View

Performance

5D 20D 120D MTD YTD
ACTU -23.6% -41.0% -70.6% -13.0% -88.9%
SPY +1.3% +2.1% +9.0% +1.5% +13.5%
vs SPY -24.9% -43.1% -79.6% -14.4% -102.4%
Key facts CIK 1652935 CUSIP 005083100 13F (30d) 3 filings 3 filers Visit website Investor relations